The Mayo Clinic, the leading US hospital, will test Nevisense in Pilot
Comunicato Precedente
Comunicato Successivo
"We are proud to work with the Mayo Clinic and believe this pilot represents an opportunity for SciBase to continue to address an unmet medical need by expanding access of the Nevisense test to more US patients at-point-of-care, when it is critical and makes a profound impact on patient care," said Pia Renaudin, CEO of SciBase.
For additional information, please contact:
Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected]
Certified Advisor (CA):
Carnegie Investment Bank AB (publ)
Phone: +46 (0)73 856 42 65
E-mail: [email protected]
About SciBase
SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.
Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/scibase/r/the-mayo-clinic--the-leading-us-hospital--will-test-nevisense-in-pilot,c4087586
The following files are available for download:
View original content:https://www.prnewswire.co.uk/news-releases/the-mayo-clinic-the-leading-us-hospital-will-test-nevisense-in-pilot-302341737.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom




